Imatinib en es it fr

Imatinib Brand names, Imatinib Analogs

Imatinib Brand Names Mixture

  • No information avaliable

Imatinib Chemical_Formula


Imatinib RX_link

Imatinib fda sheet

Imatinib FDA

Imatinib msds (material safety sheet)

Imatinib Synthesis Reference

No information avaliable

Imatinib Molecular Weight

493.603 g/mol

Imatinib Melting Point

226 oC (mesylate salt)

Imatinib H2O Solubility

Very soluble in water at pH < 5.5 (mesylate salt)

Imatinib State


Imatinib LogP


Imatinib Dosage Forms

Capsule; Tablet

Imatinib Indication

For the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML). Also indicated for the treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy. Also indicated with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

Imatinib Pharmacology

Imatinib is an antineoplastic agent used to treat chronic myelogenous leukemia. Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. In chronic myelogenous leukemia, the Philadelphia chromosome leads to a fusion protein of Abl with Bcr (breakpoint cluster region), termed Bcr-Abl. As this is now a continuously active tyrosine kinase, Imatinib is used to decrease Bcr-Abl activity.

Imatinib Absorption

Imatinib is well absorbed with mean absolute bioavailability is 98% with maximum levels achieved within 2-4 hours of dosing

Imatinib side effects and Toxicity

Side effects include nausea, vomiting, diarrhea, loss of appetite, dry skin, hair loss, swelling (especially in the legs or around the eyes) and muscle cramps

Imatinib Patient Information

Imatinib Organisms Affected

Humans and other mammals